Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Chubb
Teva
US Department of Justice
Deloitte
Moodys
Cipla
Cantor Fitzgerald
AstraZeneca

Generated: June 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,295,802

« Back to Dashboard

Which drugs does patent 9,295,802 protect, and when does it expire?

Patent 9,295,802 protects INOMAX and is included in one NDA.

Protection for INOMAX has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has nineteen patent family members in twelve countries.
Summary for Patent: 9,295,802
Title:Gas delivery device and system
Abstract: A gas delivery system including a gas delivery device, a control module and a gas delivery mechanism is described. An exemplary gas delivery device includes a valve assembly with a valve and circuit including a memory, a processor and a transceiver in communication with the memory. The memory may include gas data such as gas identification, gas expiration and gas concentration. The transceiver on the circuit of the valve assembly may send wireless optical line-of-sight signals to communicate the gas data to a control module. Exemplary gas delivery mechanisms include a ventilator and a breathing circuit. Methods of administering gas are also described.
Inventor(s): Bathe; Duncan P. (Fitchburg, WI), Klaus; John (Cottage Grove, WI), Christensen; David (Cambridge, WI)
Assignee: Mallinckrodt Hospital Products IP Limited (Dublin, IE)
Application Number:14/629,742
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,295,802
Patent Claim Types:
see list of patent claims
Delivery; Device; Use;

Drugs Protected by US Patent 9,295,802

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Mallinckrodt Hosp INOMAX nitric oxide GAS;INHALATION 020845-003 Dec 23, 1999 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,295,802

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,776,794 Nitric oxide delivery device ➤ Try a Free Trial
9,265,911 Gas delivery device and system ➤ Try a Free Trial
9,408,993 Nitric oxide delivery device ➤ Try a Free Trial
8,291,904 Gas delivery device and system ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 9,295,802

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
New Zealand 611564 ➤ Try a Free Trial
Mexico 2013007931 ➤ Try a Free Trial
Mexico 346401 ➤ Try a Free Trial
Japan 5923523 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Citi
Boehringer Ingelheim
AstraZeneca
US Department of Justice
Cipla
Argus Health
US Army
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.